CRISPR Therapeutics (CRSP) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$1.17
- EPS estimate
- −$1.26
- EPS surprise
- +7.48%
- Revenue surprise
- −90.25%
- Revenue
- $889,000.00
- Revenue estimate
- $9.1M
- Reported
- Nov 10, 2025
The latest quarter in CRISPR Therapeutics' table is Q3 2025, reported on November 10, 2025. The company posted a loss of $1.17 per share, narrower than the estimated loss of $1.26, a 7.48% beat. Revenue was $889,000, 90.25% below the $9.1 million consensus. A year earlier, Q3 2024 showed a loss of $1.01 per share on revenue of $602,000.
Losses dominate the record, with 18 of the 20 quarters shown in the red. The two profitable quarters, Q2 2021 at $9.44 per share and Q4 2023 at $1.10, came with revenue of $900.7 million and $201.2 million. In 13 of the 20 quarters revenue was below $1 million. Full-year results were EPS of $4.42 in 2021, then losses of $8.37 per share in 2022, $1.96 in 2023 and $4.37 in 2024. The first three quarters of 2025 add up to a loss of $5.15 per share. CRISPR beat the EPS estimate in 11 of 20 quarters, but revenue topped the consensus only six times.
The table has no rows after Q3 2025. Past fourth-quarter results were reported between February 11 and February 21. Newer reports will show whether revenue moves beyond the sub-$1 million level of 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 10, 2025 | −$1.26 | −$1.17 | +7.48% | $889,000.00 | SEC |
| Q2 2025 | Aug 4, 2025 | −$1.40 | −$2.40 | −71.25% | $892,000.00 | SEC |
| Q1 2025 | May 6, 2025 | −$1.24 | −$1.58 | −27.05% | $865,000.00 | SEC |
| Q4 2024 | Feb 11, 2025 | −$1.20 | −$0.44 | +63.35% | $35.7M | SEC |
| Q3 2024 | Nov 5, 2024 | −$1.41 | −$1.01 | +28.29% | $602,000.00 | SEC |
| Q2 2024 | Aug 5, 2024 | −$1.43 | −$1.49 | −4.38% | $517,000.00 | SEC |
| Q1 2024 | May 8, 2024 | −$1.36 | −$1.43 | −5.09% | $504,000.00 | SEC |
| Q4 2023 | Feb 21, 2024 | $0.07 | $1.10 | +1559.13% | $201.2M | SEC |
| Q3 2023 | Nov 6, 2023 | −$1.99 | −$1.41 | +29.12% | $0.00 | SEC |
| Q2 2023 | Aug 7, 2023 | −$2.13 | −$0.98 | +53.93% | $70.0M | SEC |
| Q1 2023 | May 8, 2023 | −$1.74 | −$0.67 | +61.52% | $100.0M | SEC |
| Q4 2022 | Feb 21, 2023 | −$2.25 | −$1.41 | +37.34% | $6,000.00 | SEC |
| Q3 2022 | Nov 1, 2022 | −$2.28 | −$2.24 | +1.66% | $94,000.00 | SEC |
| Q2 2022 | Aug 8, 2022 | −$2.22 | −$2.40 | −8.27% | $158,000.00 | SEC |
| Q1 2022 | May 9, 2022 | −$1.94 | −$2.32 | −19.64% | $940,000.00 | SEC |
| Q4 2021 | Feb 15, 2022 | −$1.76 | −$1.84 | −4.30% | $12.9M | SEC |
| Q3 2021 | Nov 3, 2021 | −$1.75 | −$1.67 | +4.72% | $824,000.00 | SEC |
| Q2 2021 | Jul 29, 2021 | $3.52 | $9.44 | +167.99% | $900.7M | SEC |
| Q1 2021 | Apr 27, 2021 | −$1.47 | −$1.51 | −2.53% | $539,000.00 | SEC |
| Q4 2020 | Feb 16, 2021 | −$1.27 | −$1.50 | −17.82% | $370,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did CRISPR Therapeutics (CRSP) last report earnings?
CRISPR Therapeutics last reported on Nov 10, 2025, covering fiscal Q3 2025.
Did CRSP beat earnings estimates?
Yes. CRISPR Therapeutics reported EPS of −$1.17 for Q3 2025 against a −$1.26 estimate — a 7.48% beat.
How much revenue did CRSP report last quarter?
CRISPR Therapeutics reported $889,000.00 in revenue for Q3 2025, against a consensus estimate of $9.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.